PEPTONIC medical AB

PMED

SE0005962206

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets 04:30:00 31/01/2024 am IST			5-day change	1st Jan Change
0.06 ^SEK	-.--%		-.--%	+3.45%

31/05	Peptonic Medical Secures European Patent for Treatment of Vulvodynia	MT
31/05	Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch	CI

Arne Ferstad Declines to Re-Elect as Director of Peptonic Medical AB

June 22, 2020 at 09:34 pm IST

Peptonic Medical AB (publ) announced that Arne Ferstad has declined re-election. The meeting will be held on June 30.

Latest news about PEPTONIC medical AB

Peptonic Medical Secures European Patent for Treatment of Vulvodynia	31/05	MT
Peptonic Medical AB Grants Patent in Europe for Relief of Provoked Vulvodynia in Women, Product Ready for Launch	31/05	CI
Peptonic Medical AB Announces Organizational Changes	21/05	CI
Sweden’s Peptonic Medical Names New CFO	15/05	MT
PEPTONIC medical AB Announces Chief Financial Officer Changes	15/05	CI
PEPTONIC medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Peptonic Medical Plans SEK61 Million Shares, Warrants Issue	17/04	MT
Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment	15/04	MT
Sweden’s Peptonic Medical Enters Benelux Distribution Deal for Women's Self-care Products	02/04	MT
Peptonic Medical AB Strengthens Its Position in Europe Through an Exclusive Distribution Agreement for Vagivital and Vernivia in the Benelux Region	02/04	CI
Peptonic Medical CFO to Depart in Mid-June	29/03	MT
PEPTONIC medical AB Announces Resignation of Albert Lindgren as CFO	28/03	CI
Farmasiet Extends Partnership with Peptonic Medical, Bringing VagVital's Product Portfolio to Norway	17/01	CI
Peptonic Medical AB Announces Patented Apoteket Offering in 293 Apoteket Stores	18/12	CI
PEPTONIC medical AB completed the acquisition of Pharmiva AB (OM : PHARM).	21/11	CI
Peptonic Medical Gains on Deal with Al Fotune for VagiVital VS Pro Distribution in UAE	13/11	MT
Peptonic Medical AB Signs Distribution Agreement with Al Fotune for United Arab Emirate	13/11	CI
Peptonic Medical AB's Self-Test for Bacterial Vivinosis to Be Sold in over 220 Apoteket Stores	08/11	CI
PEPTONIC medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	24/23/24	CI
Peptonic Medical Lands First Vaginal Self-test Order for Central American Market	19/23/19	MT
Peptonic Medical AB Receives First Order in Central America from Windsor Pharmaceuticals	19/23/19	CI
Peptonic Medical's Bacterial Vaginosis Self-test Kit to Start Selling at Walmart in US	10/23/10	MT
Pharmiva Accepts Peptonic Merger for Creation of Global Femtech Company	21/23/21	MT
PEPTONIC medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Peptonic Medical AB Appoints Albert Lindgren as Chief Financial Officer, Effective from October 21, 2023	01/23/01	CI

Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTONIC MEDICAL AB	+3.45%	8.87M
VERTEX PHARMACEUTICALS INCORPORATED	+19.33%	125B
REGENERON PHARMACEUTICALS, INC.	+13.95%	108B
BIONTECH SE	-3.53%	24.57B
ARGENX SE	+3.49%	22.82B
GENMAB A/S	-10.39%	18.19B
WUXI APPTEC CO., LTD.	-41.48%	16.54B
BEIGENE, LTD.	-12.62%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+0.99%	13.39B
SAREPTA THERAPEUTICS, INC.	+21.79%	11.1B